Modulation of experimental doxorubicin skin toxicity by β-adrenergic compounds

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Doxorubicin [Adriamycin (ADM], a potent intercalating anti-neoplastic agent, occasionally causes severe local skin toxicity if extravasated during administration. Previous experiments using intradermal (i.d.) ADM in BALB/c mice have shown limited antidotal activity for local i.d. corticosteroids in preventing ADM-induced ulceration and no effect for a number of other compounds except β-adrenergic agonists and antagonists. Three sequences of i.d. administration of β-adrenergics were evaluated in this study: a single dose immediately after 0.05 or 0.5 mg ADM; 8 daily doses of isoproterenol (ISO) or 0.9% NaCl solution, 0.05 ml after ADM; and 5 days of pre-ADM to ostensibly 'up' or 'down' -regulate β-receptor number (with propranolol and ISO, respectively). The results demonstrate consistent antidotal activity for ISO and propranolol as single antidotal injections. Terbutaline, a β2-specific agonist, was not effective as an antidote. Continuous daily ISO did not improve results, whereas continuous i.d. NaCl solution significantly increased skin lesion size and duration. ISO pretreatment significantly decreased subsequent ADM-induced ulceration, while propranolol pretreatment was not different from control. The results confirm a role for β-adrenergics in the management of experimental ADM skin ulceration and suggest that local toxicity is mediated through specific β-receptors (possibly β1) in the mouse skin.

Original languageEnglish (US)
Pages (from-to)2428-2432
Number of pages5
JournalCancer Research
Volume41
Issue number6
StatePublished - 1981

Fingerprint

Isoproterenol
Adrenergic Agents
Doxorubicin
Skin
Propranolol
Terbutaline
Antidotes
Adrenergic Agonists
Adrenergic Antagonists
Adrenal Cortex Hormones
Down-Regulation
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Modulation of experimental doxorubicin skin toxicity by β-adrenergic compounds. / Dorr, Robert T; Alberts, David S.

In: Cancer Research, Vol. 41, No. 6, 1981, p. 2428-2432.

Research output: Contribution to journalArticle

@article{b4628532041f40dfa65c1e9d2a727ed0,
title = "Modulation of experimental doxorubicin skin toxicity by β-adrenergic compounds",
abstract = "Doxorubicin [Adriamycin (ADM], a potent intercalating anti-neoplastic agent, occasionally causes severe local skin toxicity if extravasated during administration. Previous experiments using intradermal (i.d.) ADM in BALB/c mice have shown limited antidotal activity for local i.d. corticosteroids in preventing ADM-induced ulceration and no effect for a number of other compounds except β-adrenergic agonists and antagonists. Three sequences of i.d. administration of β-adrenergics were evaluated in this study: a single dose immediately after 0.05 or 0.5 mg ADM; 8 daily doses of isoproterenol (ISO) or 0.9{\%} NaCl solution, 0.05 ml after ADM; and 5 days of pre-ADM to ostensibly 'up' or 'down' -regulate β-receptor number (with propranolol and ISO, respectively). The results demonstrate consistent antidotal activity for ISO and propranolol as single antidotal injections. Terbutaline, a β2-specific agonist, was not effective as an antidote. Continuous daily ISO did not improve results, whereas continuous i.d. NaCl solution significantly increased skin lesion size and duration. ISO pretreatment significantly decreased subsequent ADM-induced ulceration, while propranolol pretreatment was not different from control. The results confirm a role for β-adrenergics in the management of experimental ADM skin ulceration and suggest that local toxicity is mediated through specific β-receptors (possibly β1) in the mouse skin.",
author = "Dorr, {Robert T} and Alberts, {David S}",
year = "1981",
language = "English (US)",
volume = "41",
pages = "2428--2432",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Modulation of experimental doxorubicin skin toxicity by β-adrenergic compounds

AU - Dorr, Robert T

AU - Alberts, David S

PY - 1981

Y1 - 1981

N2 - Doxorubicin [Adriamycin (ADM], a potent intercalating anti-neoplastic agent, occasionally causes severe local skin toxicity if extravasated during administration. Previous experiments using intradermal (i.d.) ADM in BALB/c mice have shown limited antidotal activity for local i.d. corticosteroids in preventing ADM-induced ulceration and no effect for a number of other compounds except β-adrenergic agonists and antagonists. Three sequences of i.d. administration of β-adrenergics were evaluated in this study: a single dose immediately after 0.05 or 0.5 mg ADM; 8 daily doses of isoproterenol (ISO) or 0.9% NaCl solution, 0.05 ml after ADM; and 5 days of pre-ADM to ostensibly 'up' or 'down' -regulate β-receptor number (with propranolol and ISO, respectively). The results demonstrate consistent antidotal activity for ISO and propranolol as single antidotal injections. Terbutaline, a β2-specific agonist, was not effective as an antidote. Continuous daily ISO did not improve results, whereas continuous i.d. NaCl solution significantly increased skin lesion size and duration. ISO pretreatment significantly decreased subsequent ADM-induced ulceration, while propranolol pretreatment was not different from control. The results confirm a role for β-adrenergics in the management of experimental ADM skin ulceration and suggest that local toxicity is mediated through specific β-receptors (possibly β1) in the mouse skin.

AB - Doxorubicin [Adriamycin (ADM], a potent intercalating anti-neoplastic agent, occasionally causes severe local skin toxicity if extravasated during administration. Previous experiments using intradermal (i.d.) ADM in BALB/c mice have shown limited antidotal activity for local i.d. corticosteroids in preventing ADM-induced ulceration and no effect for a number of other compounds except β-adrenergic agonists and antagonists. Three sequences of i.d. administration of β-adrenergics were evaluated in this study: a single dose immediately after 0.05 or 0.5 mg ADM; 8 daily doses of isoproterenol (ISO) or 0.9% NaCl solution, 0.05 ml after ADM; and 5 days of pre-ADM to ostensibly 'up' or 'down' -regulate β-receptor number (with propranolol and ISO, respectively). The results demonstrate consistent antidotal activity for ISO and propranolol as single antidotal injections. Terbutaline, a β2-specific agonist, was not effective as an antidote. Continuous daily ISO did not improve results, whereas continuous i.d. NaCl solution significantly increased skin lesion size and duration. ISO pretreatment significantly decreased subsequent ADM-induced ulceration, while propranolol pretreatment was not different from control. The results confirm a role for β-adrenergics in the management of experimental ADM skin ulceration and suggest that local toxicity is mediated through specific β-receptors (possibly β1) in the mouse skin.

UR - http://www.scopus.com/inward/record.url?scp=0019428202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019428202&partnerID=8YFLogxK

M3 - Article

C2 - 7237439

AN - SCOPUS:0019428202

VL - 41

SP - 2428

EP - 2432

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -